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Abstract 
 
Background 
The aetiology and risk factors for clinically important gastrointestinal bleeding (CIB) 
in adult ICU patients may differ according to onset of CIB, which could affect the 
balance between benefits and harms of stress ulcer prophylaxis (SUP). 
 
Methods 
We assessed the time to CIB in the Stress Ulcer Prophylaxis in the Intensive Care 
Unit (SUP-ICU) trial. We assessed if associations between baseline characteristics 
including allocation to SUP and CIB changed during time in the ICU, specifically in 
the later (after day two) compared to the earlier (first two days) period, using Cox 
models adjusted for SAPS II and allocation to SUP. Additionally, we described 
baseline characteristics and CIB episodes stratified by earlier/later/no CIB and 90-
day mortality status. 
 
Results 
CIB occurred in 110/3291 (3.3%) patients after a median of 6 (interquartile range 2-
13) days; 25.5% of the episodes occurred early. Higher SAPS II was consistently 
associated with increased risk of CIB (hazard ratio (HR) 1.03, 95% confidence 
interval (CI) 1.01-1.05 in the earlier period vs HR 1.02, 95% CI 1.01-1.03 in the later 
period; P=0.37); university hospital admission was associated with decreased risk of 
earlier CIB (HR 0.30, 95% CI 0.14-0.63); this significantly increased in the later 
period (to HR 0.85, 95% CI 0.53-1.37; P=0.02). Patients with later compared to 
earlier CIB received more transfusions and had more diagnostic/therapeutic 
procedures for CIB. 
 
Conclusions 
CIB mostly occurred more than two days after randomisation. University hospital 
admission was associated with significantly decreased risk of CIB in the earlier 
period only. 
 
ClinicalTrials.gov registration: NCT02467621. 
 
 
Editorial Comment 
 
When gastrointestinal bleeding is likely to occur as a complication in critically ill 
patients is unclear.  In this secondary analysis from this large trial trial of stress ulcer 
prophylaxis , the median time to bleeding detection was 6 days, and higher SAPS-II 
scores were associated with higher risk for bleeding.   
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Introduction 
 
Intensive care unit (ICU) patients are at risk for stress-related gastrointestinal (GI) 
bleeding, which is associated with adverse outcomes including death.1 In the Stress 
Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) inception cohort study 
conducted in 2013-2014, most ICU patients received stress ulcer prophylaxis (SUP) 
with acid suppressants,2 as recommended in international guidelines.3  
Clinically important GI bleeding (CIB) occurs in 2-3% of ICU patients,2 and stress 
ulcers are confirmed as the source of bleeding in less than half of critically ill patients 
with GI bleeding undergoing endoscopy.4  
 
It has been suggested that SUP may increase the risk of nosocomial pneumonia, 
Clostridium difficile infections and cardiovascular events.5,6 In a recent systematic 
review with meta-analysis and trial sequential analysis, SUP did not affect mortality.7 
SUP reduced overt GI bleeding and there was indication of, but not firm evidence for, 
a reduction in CIB.7 Additionally, the effects on adverse events, pneumonia, 
Clostridium difficile infections and myocardial ischemia were uncertain.7  
 
In the SUP-ICU inception cohort study, approximately half of the patients with CIB 
had onset of bleeding within the first two days in the ICU.2 The aetiology and risk 
factors for earlier vs later GI bleeding may differ,8 and differences in patients with 
earlier vs later CIB may affect the balance between benefits and harms of SUP. 
 
The primary objectives of this study were to assess the time to CIB and whether the 
associations between use of SUP and baseline characteristics with CIB changed 
over time, specifically, in the earlier (first two days) vs later (day three or later) 
period. Secondary objectives were to describe baseline and bleeding episode 
characteristics in patients with earlier vs later CIB. We hypothesised that time to CIB 
would be similar to the SUP-ICU inception cohort study, that associations between 
allocation to SUP and baseline characteristics could change over time, and that 
outcomes and interventions used in patients with earlier vs later CIB could differ. 
 
Methods 
 
Study design, population and approvals 
This preplanned, exploratory substudy of the SUP-ICU randomised clinical trial9 
(RCT) was conducted according to a protocol and statistical analysis plan finalised 
before the closure of the trial database on 21 March 2018 and subsequently 
published.10 The manuscript was prepared according to the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) statement.11 
Additional methodological details and the completed STROBE checklist are 
presented in the supplement. 
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The SUP-ICU trial was an investigator-initiated, international, blinded, parallel-group 
RCT, which randomised adult patients acutely admitted to an ICU with one or more 
risk factors for GI bleeding to either 40 mg pantoprazole (SUP) or matching placebo 
intravenously once daily during ICU admission for a maximum of 90 days.9 
The main exclusion criteria were previous GI bleeding during the index 
hospitalisation, ongoing treatment with acid suppressants, or contraindications to 
pantoprazole; detailed enrolment criteria are available in the supplement and 
elsewhere.9,12,13 Patients were enrolled from 4 January 2016 through 22 October 
2017, and all patients included in the primary analyses of the SUP-ICU trial were 
included in this substudy. 
 
The SUP-ICU trial was approved by the Danish Health and Medicine Agency 
(2015030166), the Committee on Health Research Ethics in the Capital Region of 
Denmark (H-16036586; with additional local/national ethics approvals in the 
participating countries as appropriate),12 by the Danish Data Protection Agency (RH-
2015-3203695) and registered at ClinicalTrials.gov (NCT02467621). 
 
Definitions 
 Overt GI bleeding: one or more of the following: haematemesis; coffee ground 
emesis; melaena; haematochezia; bloody nasogastric aspirate. 
 CIB: overt GI bleeding and at least one of the following criteria within 24 hours 
of overt GI bleeding and in the absence of other causes (clinical evaluation):  
1. decrease in systolic/diastolic/mean arterial blood pressure of ≥20 mmHg 
2. start of vasopressor or increase in vasopressor dose of ≥20% 
3. decrease in haemoglobin of ≥2 g/dL (1.24 mmol/L) 
4. transfusion of two or more units of red blood cells (RBCs). 
 Earlier CIB: first CIB episode occurring within the first two days in the ICU 
after randomisation. 
 Later CIB: first CIB episode occurring on the third day in the ICU after 
randomisation or later. 
 
Earlier and later CIB were defined according to the distribution of CIB onset times in 
the SUP-ICU inception cohort study.2,10 Additional variable definitions can be found 
in the supplement or the SUP-ICU publications.9,10,12,13  
 
Outcomes 
The primary outcome in this study was the time (number of days) to the first CIB 
episode. 
 
Additionally, we studied the following secondary outcomes: 
1. Vital status 90 days after randomisation 
2. Number of days with CIB per patient 
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3. Number of days with overt GI bleeding per patient 
4. Oesophago-gastro-duodenoscopy, laparotomy or coiling performed at least 
once on days with overt GI bleeding or CIB 
5. Number of units of RBCs transfused on days with CIB per patient 
6. Number of units of RBCs transfused in the ICU per patient 
And the following post-hoc secondary outcomes: 
7. Number of patients transfused with one or more units of RBCs on days with 
CIB 
8. Number of patients transfused with one or more units of RBCs in the ICU 
9. Number of patients with one or more overt GI bleeding episodes 
 
Vital status was primarily obtained from regional/national registries, while all other 
outcomes were registered while patients were in the ICU, including readmissions or 
transfers to other participating ICUs.9  
 
Statistics 
We present baseline data descriptively for all patients stratified by bleeding status 
(earlier/later/no CIB) and vital status at day 90 (alive/dead). Numerical data are 
presented as medians with interquartile ranges (IQRs) and categorical data are 
presented as numbers with percentages. 
 
Primary outcome and associations with baseline variables 
We present the median (IQR) time to CIB in the full trial cohort and in each 
intervention group. We assessed the associations between baseline variables 
(including treatment allocation) and time to CIB using Cox proportional hazards 
models treating death before CIB as a competing event and thus censoring patients 
when they died.14 Patients who were lost to follow-up for either CIB or mortality or 
who withdrew consent for further data registration were censored on the last day with 
available data. 
Due to the limited number of CIB events, we conducted a number of different Cox 
models. In the first model, the association between allocation to pantoprazole (vs 
placebo) and CIB onset was assessed, while additional models assessed the effect 
of each additional baseline variable and CIB in turn.10 Models were adjusted for 
treatment allocation and severity of illness using the Simplified Acute Physiology 
Score (SAPS) II15; the two models assessing these variables were only adjusted for 
the other variable. 
We estimated hazard ratios (HRs) for CIB in the earlier and later periods and 
assessed possible differences between periods by including an interaction with time 
(later period - i.e. day three or later - vs earlier period) and the variable assessed in 
each model using a time transformation function.16 Differences between periods are 
presented as HRs for the relative change in the later period compared to the earlier 
period along with P-values for the relative change. 
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Secondary outcomes 
Detailed bleeding event characteristics are presented descriptively for all patients 
and stratified by bleeding status and vital status as described above. Post-hoc, we 
decided to also present these data for patients without CIB, and to present the 
number of patients fulfilling each of the four criteria for CIB, in total and stratified by 
bleeding status and vital status. 
 
Sample size and general considerations 
The sample size was fixed, as per the SUP-ICU trial,9,12,13 and we expected 
approximately 100-120 patients with CIB.2,10  
Two-tailed P-values <0.05 and 95% confidence intervals (CIs) not including 1.00 
were considered statistically significant. We performed no corrections for multiple 
testing as all analyses presented in this study should be considered exploratory and 
hypothesis-generating.10 All analyses were conducted using R version 3.5.3 (R Core 
Team, R Foundation for Statistical Computing, Vienna, Austria). 
 
Missing data handling 
We assessed the amount of missing data for all variables. As missingness for SAPS 
II was 7.6%9 (Table 1), all Cox models were conducted using multiply imputed 
data17-19 according to the protocol.10 We generated 50 multiple imputed datasets 
using chained equations and included all baseline variables, treatment allocation, 
time to first CIB event and 90-day vital status in the imputation model. Complete 
case sensitivity analyses were also conducted. 
 
Post-hoc sensitivity analyses 
As the number of CIB events in the earlier period was lower than expected, we 
decided to conduct additional post-hoc analyses by repeating the Cox models after 
redefining the earlier and later periods according to the median number of days to 
the first CIB episode. 
 
Results 
 
We included all 3291 patients from the SUP-ICU trial who received trial medication 
and consented to use of data.9  
Baseline demographic data stratified by CIB and vital status are presented in Table 
1. Patients who either died before day 90 or had earlier CIB were older, and more 
patients with earlier CIB were admitted to non-university hospitals. There were no 
major differences in the number of comorbidities or risk factors between strata; 
however, more patients who developed earlier CIB had shock at randomisation and 
higher SAPS II, and more patients who developed CIB (regardless of onset) were on 
renal replacement therapy at randomisation.  
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Primary outcome 
In total, 110/3291 (3.3%) patients experienced CIB; 41/1644 (2.5%) in the 
pantoprazole and 69/1647 (4.2%) in the placebo group. The median time to first CIB 
episode was 6 (IQR: 2 – 13) days overall; 6 (IQR: 2 – 11) days in the pantoprazole 
group and 6 (IQR: 3 – 13) days in the placebo group. The first CIB episode occurred 
in the earlier period in 28/110 (25.5%) patients with CIB (Figure 1). 
 
The associations of baseline variables with CIB in the earlier period and the relative 
change in the later compared to the earlier period are presented in Table 2. In total, 
109/3291 (3.3%) patients were censored for either CIB or mortality before day 90.  
Higher SAPS II was consistently associated with CIB with a HR (per point increase) 
of 1.03 (95% CI: 1.01 – 1.05) in the earlier period and a HR of 1.02 (95% CI: 1.01 – 
1.03) in the later period (relative change in HR in the later compared to the earlier 
period: 0.99, 95% CI 0.96 – 1.01; P = 0.37). Admission to a university hospital was 
the only variable with a significant change in association with CIB according to time, 
with a HR of 0.30 (95% CI: 0.14 – 0.63) in the earlier period vs a HR of 0.85 (95% 
CI: 0.53 – 1.37) in the later period (relative change in HR in the later compared to the 
earlier period: 2.85, 95% CI: 1.18 – 6.90; P = 0.020).  
A number of variables were associated with statistically significant increases or 
decreases in CIB risk in the later period, including allocation to pantoprazole (HR 
0.51, 95% CI: 0.32 -0.80); emergency surgical admission (HR 0.48, 95% CI: 0.24 – 
0.99); medical admission (HR 0.34, 95% CI: 0.17 – 0.69); renal replacement therapy 
(HR 2.35, 95% CI: 1.32 – 4.20); and SOFA score (HR 1.14, 95% CI: 1.05 – 1.24 per 
point increase). 
None of these variables were associated with significantly increased or decreased 
risk in the earlier period or significant relative changes between periods.  
 
Sensitivity analyses 
The complete case sensitivity analyses were consistent with the primary analyses 
(supplement Table S1), as were most of the post-hoc sensitivity analyses 
(supplement Table S2). 
 
Secondary outcomes 
The overall 90-day mortality rate was 30.7%; 47.3% and 30.2% in patients with and 
without CIB, respectively. Detailed bleeding outcomes are presented in Table 3. 
More patients with CIB were transfused during the ICU stay, and patients with later 
CIB received more units of RBCs both during the ICU stay and on days with CIB. 
Additionally, patients with later CIB had more diagnostic or therapeutic procedures 
performed for CIB. 
The number of patients who fulfilled each of the four criteria for CIB is presented in 
supplement Table S3. 
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Discussion 
 
In this preplanned, exploratory substudy of the SUP-ICU trial, the median time to CIB 
was 6 (IQR 2 – 13) days, and later CIB was three times as common as earlier CIB. 
Higher SAPS II was consistently associated with increased risk of CIB, with no 
difference in the later compared to the earlier period. Admission to a university 
hospital was associated with lower CIB risk in the earlier period, while this 
association was significantly different with a relative increase in the later period. 
Patients with later CIB received more transfusions and had more diagnostic or 
therapeutic procedures performed for CIB than patients with earlier CIB. 
 
Being admitted to a university hospital was the only variable that significantly differed 
in the later as compared to the earlier period. A possible explanation for this finding 
might be that the most complex patients are more frequently admitted to university 
hospital ICUs, and this group of patients have longer ICU stays. While we adjusted 
the analysis for SAPS II, differences in case-mix not accounted for by the limited 
comorbidity data in SAPS II may also explain the finding. Other potential 
explanations include ICU admission earlier during the course of illness in university 
hospitals, or that differences in research resources between university and non-
university hospitals may have affected screening and randomisation. The increased 
number of transfusions and procedures in patients with later compared to earlier CIB 
may be explained to some extent by the former patients surviving longer. 
The only variable that was consistently statistically significantly associated with CIB 
was SAPS II. The two most plausible explanations for the lack of consistent 
significant findings in the other analyses are the limited number of events in each 
period and consequent low power (especially the earlier period, which contained 
fewer events and fewer significant findings than the later period), but it could also be 
explained by the adjustment for SAPS II, as most other baseline variables are in 
some way associated with increased severity of illness. Of note, in the primary SUP-
ICU results, allocation to pantoprazole led to fewer CIB events (relative risk 0.58, 
95% CI 0.40 – 0.86).9 This is consistent with the findings of this substudy, where 
pantoprazole was associated with significantly decreased CIB in the later period. 
Although the CIs for the earlier period and the relative change include no difference, 
it is interesting that point estimates suggest decreased CIB risk with PPI in both 
periods, but the largest effect in the later period.   
 
The lower proportion of earlier CIB compared to the SUP-ICU inception cohort study2 
may be partially explained by the time from ICU admission to randomisation (median 
15 (IQR: 5 – 28) and 14 (IQR: 6 – 23) hours in the pantoprazole and placebo groups, 
respectively).9 Some patients may have experienced GI bleeding shortly after ICU 
admission leading to prescription of pantoprazole and exclusion from the SUP-ICU 
trial upon screening. The times to CIB in this study are more comparable to 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
estimates from a 20-year old RCT, where approximately 1 in 4 patients with CIB had 
their first CIB episode within five days after randomisation.20 
 
Strengths and limitations 
Strengths of this study reflect those of the SUP-ICU trial,9 including the large sample 
size, pragmatic design, high external validity and data quality; our missing data 
handling strategy; and prepublication of the protocol and statistical analysis plan,10 
which increases transparency and trustworthiness.21-24  
The study has a number of limitations too, and the results should be considered 
exploratory and hypothesis-generating as stated in the protocol.10 First, despite the 
large size of the SUP-ICU trial, the number of CIB events was limited, as expected, 
which led to lower precision and a risk of not detecting true differences (type 2 
errors). However, potential differences in associations in the two time periods that 
did not reach statistical significance due to low power are probably of limited clinical 
relevance due to the rarity of CIB. Second, as the SUP-ICU trial only included 
patients with at least one risk factor for GI bleeding, the results may not be directly 
transferable to ICU patients without any of these risk factors. Third, ICUs 
participating in the SUP-ICU trial may differ from ICUs not participating in how GI 
bleeding is recognised and treated. Fourth, our analysis strategy was relatively 
simple, only adjusted for two variables (SAPS II and allocation to pantoprazole), and 
only assessed time differences according to one point in time. Other adjustment 
strategies could have been considered, and associations with CIB if not adjusted for 
SAPS II or use of SUP may be different. However, the rarity of CIB would make 
more complex models fragile and conducting additional analyses would increase the 
risk of chance findings (type 1 errors). Fifth, while our definitions of earlier vs later 
CIB were based on previous research,2 the cut-off of two days may be considered 
somewhat arbitrary. Importantly, though, results were similar in the sensitivity 
analyses conducted after redefining the time periods. Finally, the assessment of 
secondary outcomes according to time of first CIB event may be subject to survival 
bias and a competing risk of death before CIB25, as the most severely ill patients 
may be more likely to develop CIB, but also more likely die before that happens. We 
did not account for this in the descriptive presentations of secondary outcome data.  
 
In conclusion, half of all CIB events happened in the first week, and only a quarter of 
CIB events occurred in the earlier period. Higher SAPS II was consistently 
associated with increased risk of CIB, and admission to a university hospital was the 
only variable with a significantly different association in the time periods considered, 
with a decreased risk in the earlier period and a relatively increased risk in the later 
period. Patients with later CIB received more transfusions and had more diagnostic 
or therapeutic procedures performed for CIB than those with earlier CIB. 
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Tables 
Table 1 Baseline characteristics stratified by outcomes 
Variable All patients 
(n = 3291) 
Earlier CIB 
and alive
a
 
(n = 16) 
Earlier CIB 
and dead
a
 
(n = 12) 
Later CIB 
and alive
a
 
(n = 42) 
Later CIB 
and dead
a
 
(n = 40) 
No CIB and 
alive
a
 
(n = 2215) 
No CIB and 
dead
a
 
(n = 957) 
Age (years) 67.0 (56.0 - 
75.0) 
71.0 (54.8 - 
75.2) 
74.0 (66.2 - 
77.8) 
64.0 (57.2 - 
72.0) 
71.5 (64.5 - 
75.2) 
65.0 (52.0 - 
73.0) 
72.0 (64.0 - 
79.0) 
Male gender 2106 
(64.0%) 
10 (62.5%) 7 (58.3%) 26 (61.9%) 28 (70.0%) 1440 
(65.0%) 
588 (61.4%) 
Number of 
comorbidities
b 
0.0 (0.0 - 
1.0) 
0.0 (0.0 - 
1.0) 
1.0 (0.0 - 
1.0) 
0.0 (0.0 - 
1.0) 
0.0 (0.0 - 
1.0) 
0.0 (0.0 - 
1.0) 
0.0 (0.0 - 
1.0) 
Chronic lung 
disease
b
 
657 
(20.0%) 
4 (25.0%) 6 (50.0%) 9 (21.4%) 7 (17.5%) 371 (16.7%) 260 (27.2%) 
Previous myocardial 
infarction
b
 
298 (9.1%) 0 (0.0%) 0 (0.0%) 5 (11.9%) 3 (7.5%) 174 (7.9%) 116 (12.1%) 
Chronic heart failure 
(NYHA III-IV)
 b
 
199 (6.0%) 0 (0.0%) 0 (0.0%) 2 (4.8%) 2 (5.0%) 103 (4.7%) 91 (9.5%) 
Immunosuppression
b
 62 (1.9%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 1 (2.5%) 35 (1.6%) 25 (2.6%) 
Haematological 
malignancy
b
 
119 (3.6%) 1 (6.2%) 0 (0.0%) 1 (2.4%) 4 (10.0%) 56 (2.5%) 57 (6.0%) 
Metastatic cancer
b
 111 (3.4%) 1 (6.2%) 1 (8.3%) 0 (0.0%) 3 (7.5%) 46 (2.1%) 60 (6.3%) 
AIDS
b
 7 (0.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (5.0%) 4 (0.2%) 1 (0.1%) 
Admitted to 
university hospital 
2372 
(72.1%) 
9 (56.2%) 3 (25.0%) 32 (76.2%) 25 (62.5%) 1656 
(74.8%) 
638 (66.7%) 
Time from ICU 
admission to 
randomisation 
(hours) 
15.0 (5.0 - 
26.0) 
10.5 (2.8 - 
25.8) 
14.0 (4.5 - 
21.2) 
23.0 (10.0 - 
40.8) 
18.0 (6.5 - 
35.2) 
14.0 (5.0 - 
26.0) 
15.0 (5.0 - 
26.0) 
Admission type:        
- Elective surgical
c
 200 (6.1%) 1 (6.2%) 0 (0.0%) 6 (14.3%) 4 (10.0%) 139 (6.3%) 50 (5.2%) 
- Emergency 
surgical 
1048 
(31.8%) 
5 (31.2%) 3 (25.0%) 16 (38.1%) 14 (35.0%) 756 (34.1%) 249 (26.0%) 
- Medical 2043 
(62.1%) 
10 (62.5%) 9 (75.0%) 20 (47.6%) 22 (55.0%) 1320 
(59.6%) 
658 (68.8%) 
Number of risk 
factors
d 
2.0 (2.0 - 
3.0) 
2.0 (1.8 - 
2.0) 
2.0 (2.0 - 
2.2) 
2.0 (1.0 - 
3.0) 
2.0 (2.0 - 
3.2) 
2.0 (2.0 - 
3.0) 
2.0 (2.0 - 
3.0) 
Chronic liver 
disease
d
 
94 (2.9%) 0 (0.0%) 0 (0.0%) 1 (2.4%) 2 (5.0%) 46 (2.1%) 43 (4.5%) 
Chronic renal 
replacement 
therapy
d
 
37 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 19 (0.9%) 18 (1.9%) 
Acute coagulopathy
d
 577 
(17.5%) 
2 (12.5%) 1 (8.3%) 6 (14.3%) 13 (32.5%) 346 (15.6%) 209 (21.8%) 
History of 
coagulopathy
d
 
208 (6.3%) 0 (0.0%) 0 (0.0%) 2 (4.8%) 4 (10.0%) 117 (5.3%) 85 (8.9%) 
Use of 
anticoagulants
d
 
739 
(22.5%) 
2 (12.5%) 2 (16.7%) 10 (23.8%) 7 (17.5%) 443 (20.0%) 274 (28.6%) 
Use of NSAID or 
acetylsalicylic acid
d
 
533 
(16.2%) 
0 (0.0%) 2 (16.7%) 5 (11.9%) 4 (10.0%) 371 (16.7%) 150 (15.7%) 
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Use of intravenous 
thrombolysis
d
 
47 (1.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (5.0%) 37 (1.7%) 8 (0.8%) 
Invasive mechanical 
ventilation
d
 
2589 
(78.7%) 
12 (75.0%) 9 (75.0%) 32 (76.2%) 31 (77.5%) 1739 
(78.5%) 
759 (79.3%) 
Shock at inclusion
d
 2467 
(75.0%) 
14 (87.5%) 11 (91.7%) 31 (73.8%) 35 (87.5%) 1608 
(72.6%) 
762 (79.6%) 
Renal replacement 
therapy at inclusion
d
 
258 (7.8%) 3 (18.8%) 2 (16.7%) 5 (11.9%) 10 (25.0%) 147 (6.6%) 91 (9.5%) 
SAPS II
e 
48.0 (38.0 - 
59.0) 
52.0 (41.5 - 
58.0) 
68.0 (60.8 - 
77.0) 
47.5 (36.0 - 
55.2) 
54.0 (47.0 - 
65.5) 
45.0 (36.0 - 
56.0) 
55.0 (45.0 - 
66.0) 
SOFA score
e
 9.0 (7.0 - 
11.0) 
8.0 (6.5 - 
10.0) 
11.0 (9.5 - 
12.2) 
9.0 (6.0 - 
11.0) 
11.0 (9.0 - 
13.0) 
8.0 (6.0 - 
10.0) 
10.0 (7.0 - 
12.0) 
Allocated to 
pantoprazole (vs 
placebo) 
1644 
(50.0%) 
7 (43.8%) 6 (50.0%) 9 (21.4%) 19 (47.5%) 1116 
(50.4%) 
485 (50.7%) 
 
Baseline data stratified by clinical outcomes. For detailed definitions, see 
supplement or elsewhere.9,10,12,13  
a Stratified by any CIB episode (earlier/later/none) and vital status 90 days after 
inclusion. The 9 patients with missing vital status at day 90 are only included in the 
“All patients” column; none of these patients had CIB. 
b The number of comorbidities includes all comorbidities marked with b. 
c Only acutely admitted patients were included; elective surgical patients were 
patients who had elective surgery in the seven days prior to ICU admission and were 
then acutely admitted to a participating ICU due to complications or events 
happening after the elective surgery, without fulfilment of the criteria for being 
classified as acute surgical admission. 
d The number of risk factors includes all risk factors marked with d. 
e In total, 249 patients (7.6%) had missing data for SAPS II and 193 patients (5.9%) 
had missing data for the SOFA score. No data were missing for any other baseline 
variables presented in this table. 
Abbreviations: AIDS: acquired immune deficiency syndrome; CIB: clinically important 
gastrointestinal bleeding; ICU: intensive care unit; NYHA: New York Heart 
Association functional classification; NSAID: non-steroidal anti-inflammatory drugs; 
SAPS II: Simplified Acute Physiology Score II; SOFA score: Sequential [Sepsis-
related] Organ Failure Assessment score.
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Table 2 Associations between baseline characteristics and CIB in the earlier 
and later periods 
 
Variable Hazard ratio in the 
earlier period (95% 
CI) 
Hazard ratio in the 
later period (95% 
CI) 
Relative change in 
hazard ratio in the 
later compared to 
the earlier period 
(95% CI) 
P-value for 
test of 
change in 
association 
with time 
Allocated to pantoprazole 
(vs placebo) 
0.85 (0.40 – 1.78) 0.51 (0.32 – 0.80) 0.60 (0.25 – 1.42) 0.24 
Age (per year) 1.01 (0.98 – 1.04) 1.01 (0.99 – 1.02) 1.00 (0.97 – 1.03) 0.85 
Male gender 0.85 (0.40 – 1.82) 1.04 (0.66 – 1.64) 1.22 (0.50 – 2.95) 0.66 
Number of comorbidities
a
 
(per comorbidity) 
0.99 (0.59 – 1.69) 1.11 (0.82 – 1.51) 1.12 (0.61 – 2.06) 0.71 
Admitted to university 
hospital 
0.30 (0.14 – 0.63) 0.85 (0.53 – 1.37) 2.85 (1.18 – 6.90) 0.020 
Time from ICU admission 
to randomisation (per 
hour) 
0.99 (0.97 – 1.01) 1.00 (1.00 – 1.01) 1.01 (0.99 – 1.03) 0.17 
Admission type: 
- Reference: elective 
surgical
b 
    
- Emergency surgical 1.21 (0.15 – 9.73) 0.48 (0.24 – 0.99) 0.40 (0.04 – 3.59) 0.41 
- Medical 1.38 (0.18 – 10.35) 0.34 (0.17 – 0.69) 0.25 (0.03 – 2.08) 0.20 
Number of risk factors
c 
(per risk factor) 
0.80 (0.55 – 1.16) 1.08 (0.88 – 1.32) 1.36 (0.89 – 2.07) 0.16 
Chronic liver disease
c
 Too few events
f
 Too few events
f 
Too few events
f
 Too few 
events
f
 
Chronic renal replacement 
therapy
c
 
Too few events
f
 Too few events
f
 Too few events
f
 Too few 
events
f
 
Acute coagulopathy
c
 0.53 (0.16 – 1.76) 1.38 (0.83 – 2.32) 2.61 (0.71 – 9.61) 0.15 
History of coagulopathy
c
 Too few events
f
 Too few events
f
 Too few events
f
 Too few 
events
f
 
Use of anticoagulants
c
 0.54 (0.19 – 1.56) 0.89 (0.52 – 1.52) 1.64 (0.50 – 5.37) 0.41 
Use of NSAID or 
acetylsalicylic acid
c
 
0.40 (0.10 – 1.69) 0.62 (0.31 – 1.25) 1.55 (0.31 – 7.66) 0.59 
Use of intravenous 
thrombolysis
c
 
Too few events
f
 Too few events
f
 Too few events
f
 Too few 
events
f
 
Invasive mechanical 
ventilation
c
 
0.70 (0.29 – 1.64) 0.80 (0.48 – 1.34) 1.15 (0.42 – 3.12) 0.78 
Shock at inclusion
c
 2.50 (0.75 – 8.30) 1.31 (0.76 – 2.27) 0.52 (0.14 – 1.95) 0.34 
Renal replacement 
therapy at inclusion
c
 
2.18 (0.82 – 5.78) 2.35 (1.32 – 4.20) 1.08 (0.35 – 3.31) 0.89 
SAPS II (per point) 1.03 (1.01 – 1.05) 1.02 (1.01 – 1.03) 0.99 (0.96 – 1.01) 0.37 
SOFA score (per point) 1.06 (0.94 – 1.21) 1.14 (1.05 – 1.24) 1.08 (0.94 – 1.23) 0.28 
 
Associations between baseline variables and CIB according to time. All models 
assessed the association between each baseline variable and time to CIB in turn 
using Cox regressions adjusted for treatment allocation (pantoprazole vs placebo) 
and SAPS II, with an interaction term between the variable and time (specifically, 
assessing the relative change in association in the later compared to the earlier 
period). 
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a Number of comorbidities included the following comorbidities: chronic lung disease; 
previous myocardial infraction; chronic heart failure (NYHA III-IV); 
immunosuppression; haematological malignancy; metastatic cancer; and AIDS. 
b Only acutely admitted patients were included; elective surgical patients were 
patients who had elective surgery in the seven days prior to ICU admission and were 
then acutely admitted to a participating ICU due to complications or events 
happening after the elective surgery, without fulfilment of the criteria for being 
classified as acute surgical admissions. 
c Variables marked c are included in the number of risk factors. 
d “Too few events” indicates that the analysis was not possible as no patients had 
both the variable and CIB in the earlier and/or later period. 
Abbreviations: AIDS: acquired immune deficiency syndrome; CI: confidence interval; 
CIB: clinically important gastrointestinal bleeding; ICU: intensive care unit; NSAID: 
non-steroidal anti-inflammatory drugs; NYHA: New York Heart Association functional 
classification; SAPS II: Simplified Acute Physiology Score II; SOFA score: Sequential 
[Sepsis-related] Organ Failure Assessment score. 
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Table 3 Detailed bleeding outcome characteristics 
 
Outcome All 
patients 
(n = 
3291) 
Earlier 
CIB and 
alive
a
 (n = 
16) 
Earlier 
CIB and 
dead
a
 (n = 
12) 
Later CIB 
and alive
a
 
(n = 42) 
Later CIB 
and dead
a
 
(n = 40) 
No CIB 
and alive
a
 
(n = 2215) 
No CIB 
and dead
a
 
(n = 957) 
Number of days with CIB 
episodes in each patient 
0.0 (0.0 - 
0.0) 
1.0 (1.0 - 
2.2) 
1.0 (1.0 - 
1.0) 
1.0 (1.0 - 
2.0) 
1.0 (1.0 - 
3.0) 
NA NA 
Number of days with overt GI 
bleeding episodes in each patient 
0.0 (0.0 - 
0.0) 
1.5 (1.0 - 
3.2) 
1.0 (1.0 - 
1.0) 
2.0 (1.0 - 
3.0) 
1.0 (1.0 - 
4.0) 
0.0 (0.0 - 
0.0) 
0.0 (0.0 - 
0.0) 
Any procedure performed 
(oesophago-gastro-
duodenoscopy/laparotomy/coiling) 
50 (1.5%) 5 (31.2%) 1 (8.3%) 23 
(54.8%) 
19 (47.5%) 2 (0.1%) 0 (0.0%) 
Number of units of red blood cells 
transfused on days with CIB per 
patient 
0.0 (0.0 - 
0.0) 
1.0 (0.0 - 
2.5) 
1.5 (0.0 - 
2.8) 
2.0 (0.0 - 
4.8) 
2.0 (1.0 - 
9.5) 
NA NA 
Number of units of red blood cells 
transfused per patient 
0.0 (0.0 - 
1.0) 
3.5 (0.0 - 
8.0) 
2.5 (0.8 - 
6.2) 
7.0 (2.2 - 
14.0) 
7.5 (2.8 - 
19.2) 
0.0 (0.0 - 
1.0) 
0.0 (0.0 - 
1.0) 
Any red blood cell transfusions on 
days with CIB
 
78 (2.4%) 8 (50.0%) 8 (66.7%) 30 
(71.4%) 
32 (80.0%) NA NA 
Any red blood cell transfusions 
during ICU stay 
1023 
(31.1%) 
10 (62.5%) 9 (75.0%) 35 
(83.3%) 
36 (90.0%) 624 
(28.2%) 
304 
(31.8%) 
Any overt GI bleeding episodes 236 
(7.2%) 
16 
(100.0%) 
12 
(100.0%) 
42 
(100.0%) 
40 
(100.0%) 
72 (3.3%) 54 (5.6%) 
 
Detailed bleeding outcome characteristics during days in the intensive care unit in 
the 90 days following inclusion (secondary outcomes). No data were missing for any 
of the outcome variables presented in this table. 
a Stratified by any CIB episode (earlier/later/none) and vital status 90 days after 
inclusion. 
The 9 patients with missing vital status at day 90 are only included in the “All 
patients” column; none of these patients had CIB. 
Abbreviations: CIB: clinically important gastrointestinal bleeding; GI: gastrointestinal; 
ICU: intensive care unit; NA: not applicable. 
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Figure titles and legends 
Figure 1 Time of CIB episodes 
 
 
 
Number of patients with CIB according to days from randomisation in the full trial 
cohort and stratified by treatment allocation. A similar figure for overt GI bleeding is 
presented in the supplement. 
The dark part of each bar represents patients who had their first CIB episode on this 
day, the light part of each bar represents patients who had a CIB episode on this day 
but previously had another episode. 
Abbreviations: CIB: clinically important gastrointestinal bleeding.  
